MLANA and melanoma: In Phase II, an open-label, randomized, two-arm study, the effects of different adjuvants were compared, where Arm A means Poly-ICLC-matured DC+PolyICLC and Arm B means Montanide ISA-51-VG+Poly-ICLC, as adjuvants for NY-ESO-1 and Melan-A/MART-1 long peptides in patients with melanoma in complete clinical remission but at high risk of disease recurrence (NCT02334735).